リンバチ酸は,HPX- MAPK経路を通じてレネヴァチニブ耐性を促進する
Jinlu Han1, Chen Wang1, Yun Song1
1Department of Gastroenterology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, 1111 Xianxia Road, Shanghai 200336, China.
Ecotoxicology and environmental safety
|August 26, 2025
まとめ
肝細胞がん (HCC) のレネヴァチニブ耐性を誘発する要因は,HPX遺伝子のダウンレギュレーションである. HPXの回復は,HCCの治療における薬剤耐性の克服の可能性を示しています.
科学分野:
- ヘパトビリアル医学
- 環境毒理学
- 分子腫瘍学
背景:
- レンバチニブ耐性症は肝細胞癌 (HCC) の治療において重要な課題となっています.
- HCCにおける治療耐性への貢献における一般的な可塑剤である環境フェタラートの役割は十分に理解されていません.
研究 の 目的:
- HCCにおけるフタラート曝露とレンバチニブ耐性との潜在的な関連を調査する.
- この抵抗メカニズムに関与する重要な遺伝子と分子経路を特定する.
主な方法:
- 統合されたネットワーク毒性学,分子ドッキング,およびトランスクリプトミア分析.
- リンヴァチニブ耐性遺伝子 (PLRGs) を特定し,予後リスクモデルを構築した.
- 機能検査,ウエスタン・ブロット,および in vivo マウスモデルを用いて検証した.
主要な成果:
- HPXを含む8つの遺伝子に基づいた検証されたリスクモデルを持つ40のPLRGsを特定しました.
- HPXはHCC組織と抵抗性細胞系において低調され,特定のフタル酸と相互作用することが判明した.
- HPXの過剰発現はHCCの進行とレンバチニブ耐性を抑制し,フタラート暴露はMAPK経路を活性化し,HPXはそれを抑制した.
結論:
- リンバチニブに対するレジスタンスには,HPX- MAPKシグナリング軸が寄与する.
- HPXは,HCCにおけるレンバチニブ耐性を克服するための予後バイオマーカーおよび治療標的として潜在性を示しています.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K


